FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Tracimigram, 2.01.200 io								

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									

hours per response:

0.5

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*					2. Issuer Name and Ticker or Trading Symbol Kura Oncology, Inc. [KURA]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
WILSON TROY EDWARD				-	ixura Oncology, me. [KOKA]						2	Director	•	10% O	vner		
													(give title	Other (specify		
(Last)	(F	irst)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year)							below) below)					
C/O KURA ONCOLOGY, INC.					01/24/2018						President and CEO						
3033 SCIENCE PARK ROAD, SUITE 220																	
				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. In	6. Individual or Joint/Group Filing (Check Applicable					
(Street)												Line)					
SAN DIEGO CA 92121			92121								2	X Form filed by One Reporting Person					
												Form fil Person		han One Repo	ting		
(City)	(S	tate)	(Zip)									r erson					
		Ta	ble I - Non-De	erivati	ve Se	curities	s Ac	quired, Di	isposed o	of, or Be	neficially	Owned					
1. Title of Security (Instr. 3) 2. Transa Date (Month/D				е	2A. Deemed Execution Date, if any (Month/Day/Yea		Code (Instr.			ed (A) or str. 3, 4 and 5	Beneficia Owned Fo	s Form ally (D) o ollowing (I) (Ir	. Ownership orm: Direct D) or Indirect) (Instr. 4)	7. Nature of Indirect Beneficial Ownership			
								Code V	Amount	(A) o (D)	r Price	Reported Transacti (Instr. 3 a	on(s)		(Instr. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned																
			(e.g	., puts	s, call	ls, warr	ants	s, options,	converti	ble secu	ırities)						
1. Title of Derivative Security (Instr. 3)	vative Conversion Date Execution Date irity or Exercise (Month/Day/Year) if any		Execution Date,	Code (Instr.		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)		
											Amount		(Instr. 4)	,			
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	or Number of Shares						
Option to purchase common stock	\$20	01/24/2018		A		275,000		(1)	01/23/2028	Common Stock	275,000	\$0.00	275,000	D			

Explanation of Responses:

1. This option vests in 48 equal monthly installments commencing on the grant date.

Remarks:

<u>Heidi Henson, Attorney-in-fact</u> <u>for Troy Wilson</u>

01/26/2018

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.